Key Dates

Related Announcements

NOT-DA-23-016 - Notice of Early Termination of NOT-DA-23-005, Notice of Special Interest (NOSI): HEAL Initiative: Biospecimen Collection in Pregnancy

PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

Issued by

National Institute on Drug Abuse (NIDA)

All applications to this funding opportunity announcement should fall within the mission of the Institutes/Centers. The following NIH Offices may co-fund applications assigned to those Institutes/Centers.

Office of Research on Women's Health (ORWH)

Purpose

This NOSI invites applications for administrative supplements

to existing awards to add and/or expand biospecimen collection during and immediately after pregnancy to build prospective pathophysiological models of maternal, neonatal, and infant risk and disease related to prenatal opioid use or exposure during pregnancy. Prenatal opioid use during pregnancy can significantly increases the risk for neonatal opioid withdrawal syndrome (NOWS) in newborns, and contribute to a host of maternal health and behavioral outcomes, including altered maternal caregiving behaviors and chronic stress. However, there is little known about the pathophysiological mechanisms that mediate the connection between opioid use during pregnancy and adverse neonatal, infant and/or maternal health outcomes, and as a result, few preventive interventions exist to mitigate the risk and severity of maternal addiction as well as neonatal illness because of prenatal exposure.

Applicants can propose to add and/or expand biospecimen collections and/or analyses where this falls within the existing scope of the parent award. Funds can be requested for staff time, supplies, equipment, storage, postage, and other costs associated with collections and/or analyses. Proposed collections can include but are not limited to urine, blood, nails, placenta, stool, and/or breastmilk, and should be within the context of a clear pathophysiological model that will support and contribute further understanding of the consequences of substance use and exposure during pregnancy, and align with parent award objectives. Applicants should limit maternal and developmental outcomes from the pregnancy period through the first year of life following birth.

Responsive applications include, but are not limited to

1. Identification of genetic and epigenetic mechanisms of substance use exposure on neonatal, infant, and maternal outcomes.
2. Quantification of substance use exposures during pregnancy and its influence on neonatal, infant, and maternal outcomes over the course of pregnancy and/or following birth.
3. Identification of factors that may influence the pathophysiological connections between maternal opioid use, fetal growth, and neonatal outcomes, including but not limited to maternal and environmental stress, maternal nutrition, and birth interventions (e.g., use of neuraxial anesthesia)

Eligibility

Program Directors/Principal Investigators (PDs/PIs) of the following activity codes are eligible for the program: DP1, DP2, DP4, DP5, G12, G20, P01, P20, P2C, P30, P40, P41, P42, P50, P51, P60, PM1, PN2, R00, R01, R03, R15, R16, R18, R21, R21/R33, R24, R25, R33, R34, R35, R37, R38

R61/R33, R90, RC1, RC2, RC3, RC4, RF1, RM1, SC1, SC2, SC3, S06, S21

Cooperative

UL1, U01, U10, U13, U18, U19, U24, U2C

Cooperative

U41, U42, U44, U54, U56, UC2, UC4, UF1, UG1, UG3/UH3, UH2, UH2/UH3, UH3, UM1, UM2

Research Career Programs

K01, K02, K07, K08, K12, K14, K18, K22, K23, K24, K25, K26, K99, KL2

Training Programs

T15, T32, T34, T35, T37, T90, TL1

Application and Submission Information

This notice applies to due dates on or after September 25, 2022 and subsequent receipt dates through October 8, 2023.

Submit applications for this initiative using the following funding opportunity announcement (FOA) or any reissue of this announcement through the expiration date of this notice.

• PA-20-272 - Administrative Supplements to Existing NIH Grants and Cooperative Agreements (Parent Admin Supp Clinical Trial Optional)

All instructions in the SF424 (R&R) Application Guide and the funding opportunity announcement used for submission must be followed, with the following additions:

• For funding consideration, applicants must include NOT-DA-23-005" (without quotation marks) in the Agency Routing Identifier field (box 4B) of the SF424 R&R form. Applications without this information in box 4B will not be considered for this initiative.

Inquiries

Please direct all inquiries to:

Janani Prabhakar
National Institute on Drug Abuse
Telephone: 301-827-4729
Email: [email protected]

Michelle Freund
National Institute on Drug Abuse
Telephone: 301-827-4128
Email: [email protected]